Randox pledges commitment to business in Europe
Randox pledges commitment to business in Europe
Global healthcare firm Randox Laboratories has pledged its commitment to maintaining and developing its business relationships with Europe, as a group of 20 representatives from the diagnostics company have travelled to Greece this week, to take part in one of Europe’s largest diagnostics conference in Athens.
EuroMedLab, which is run by the European Congress of Clinical Chemistry and Laboratory Medicine, is attended by thousands of healthcare professionals from across the globe, and offers Randox the opportunity to showcase their capabilities and to network with key decision makers.
Managing Director of Randox, Dr. Peter FitzGerald, commented on what the company hopes to achieve by attending EuroMedLab;
“We highly value the business we do within the European market and have successfully made a name for ourselves in the diagnostics industry in these countries. We already have a number of key sales offices and distribution centres in the likes of France, Germany, Portugal, Italy, Spain and Poland, but there is so much more we can do. Attending key networking events such as EuroMedLab is vital because it allows us the opportunity to meet with our existing customers and partners, to nurture and develop these relationships, and of course establish new ones.”
At the EuroMedLab conference the delegation team of Randox scientists, business development executives and market researchers will be making a series of announcements and presentations for new products including an innovative stroke diagnostic, newly discovered biomarkers for coronary heart disease risk, and the latest in laboratory quality assurance software.
The team will also present for the first time the Evidence Evolution analyser, a biochip testing platform capable of delivering accurate results from more than 2600 tests an hour including, but not exclusive to, cancer surveillance, fertility, heart, nutritional, digestive and diabetes health.
Dr. FitzGerald continued;
“At Randox we invest up to 16% of our turnover in R&D and we therefore have more new tests in development than any other diagnostics company in the world. This puts us in a very unique position in the market because our new developments, which are focused in areas where they are needed the most, successfully address the most urgent health issues.
“In light of recent political developments, there will of course be particular business challenges in Europe, but at Randox we will maintain our commitment to nurturing our relationships with key business partners in Europe and to seeking new opportunities in international markets such as the US.”
EuroMedLab runs from the 11th – 15th June 2017 at the Megaron Athens International Conference Centre in Athens. Randox can be found at booth #13 in the Skalkotas Hall Foyer.
For further information about EuroMedLab visit http://euromedlab.randox.com/ or contact Randox PR on 028 9445 1016 or email RandoxPR@randox.com
Randox unveils Future of Diagnostics Technology at Annual Global Distributorsā Conference
The future of diagnostic healthcare has been unveiled at the Randox Science Park in Antrim, as the company’s annual global distributors’ conference gets underway. Delegates from more than 90 countries are taking part in the world-leading healthcare firm’s three-day event at the Hilton Hotel in Templepatrick.
As well as discussions about developments in reagents and quality control products, participants enjoyed demonstrations of Randox’s patented Biochip Array Technology and its extensive range of analysers from the RX Series.
Melansha Fernando from Alpha and Omega Diagnostics in Sri Lanka said,
“Randox has released so many new products recently that laboratories in my country are increasingly interested in what it can offer. As a result I felt it important to come here to learn more about the new technologies. The truly global nature of the company has been impressed upon me after meeting colleagues from so many different countries – I’m delighted to have been able to take part.”
Speaking at the conference, Dr. Peter Fitzgerald said,
“All exporters are aware of the considerable challenges we must overcome in order to do business in the global market but year on year our teams across the world have helped to drive our success. One of the biggest challenges Randox faces is the one we put to ourselves, to deliver truly transformative technologies and improve health worldwide. We recently celebrated our £1 billionth sale and we now look to build on that achievement and accelerate our rate of growth. All of our profits go straight to either R&D, or the development of our infrastructure, so strong growth is key to our goal of revolutionising diagnostics and saving lives across the world.”
Susan Hammond, Global Reagents Sales Manager said,
“It is a pleasure to see the diversity of our distributors gathered together in one room, and recognize how far we have come as an international company. We dedicated Thursday to focusing on building relationships with our worldwide distributors to ensure that they attain the best product knowledge available. Over 100,000 end users employ Randox products and every second of every day 80 Randox tests are used across the world, and it is vital our distributors are kept up to date with every new development.”
For more information on the Distributors’ Conference contact Amy in our PR Team by calling 028 9445 1016 or email amy.mcilwaine@randox.com
